A Phase II of Rituximab in Myasthenia Gravis (NN 103)

Grant

Date/time Interval

  • April 21, 2014 - August 31, 2018

    • Awarded By

    Total Award Amount

  • 16536.00

    • Direct Costs

  • 11249.00

    • Sponsor Award Id

    • Contributor

  • Eroboghene Ubogu   Investigator